Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Hospices Civils de Lyon
Modality
protein_peptide
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06158334CT.gov Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) | — | Unknown | — | — | — |
NCT03248141CT.gov Understanding Hemophilia A and B Drug Dosage Administration Patterns | — | Terminated | — | — | — |
NCT03055611CT.gov A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B | — | Completed | — | — | — |
NCT02392156CT.gov Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia A
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eftrenonacog Alfa (this asset) | Hospices Civils de Lyon | Unk | D · 30 |
| Turoctocog Alfa | Novo Nordisk A/S | P4 | A |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Rurioctocog Alfa Pegol | Takeda | P4 | BBB |
| N8-GP | Novo Nordisk A/S | P3 | BBB |
| Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-Chain | Novo Nordisk A/S | P3 | BBB |
| bay94-9027 | Bayer | P4 | BBB |
| Emicizumab | Emory University | P4 | BBB |
| Factor Viii (Human) | Hoffmann-La Roche | P4 | BBB |
+36 more in the Hemophilia A cohort
Other indications for Eftrenonacog Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Severe Hemophilia B | — | P3 | BB · 66 |
| Hemophilia B | — | P3 | BB · 64 |
| Inherited Blood Coagulation Disorder | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Turoctocog AlfaNovo Nordisk A/SA
- Eptacog Alfa (Activated)AryoGen Pharmed Co.A
- Rurioctocog Alfa PegolTakedaBBB
- N8-GPNovo Nordisk A/SBBB
- Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-ChainNovo Nordisk A/SBBB
Citation
Floatz Terminal. Eftrenonacog Alfa in Hemophilia A. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eftrenonacog-alfa-hemophilia-a-120465
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →